Back to Search
Start Over
Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
- Source :
- Frontiers in Oncology, Frontiers in Oncology, Vol 10 (2021)
- Publication Year :
- 2020
-
Abstract
- Multiple myeloma (MM) is an incurable disease with a limited life expectancy of five years from diagnosis. Uncontrolled disease or infections are the main causes of mortality. Daratumumab, a monoclonal antibody against CD38, is approved to treat patients with MM. Its target, CD38, is expressed not only on MM cells but also on common lymphoid precursors and subsets of normal lymphocytes. Daratumumab-induced lymphopenia is common, but its clinical significance is understudied. In this study, we report the baseline characteristics, rates of severe lymphopenia, infections, and clinical trajectory of multiple myeloma patients (n = 100) treated with daratumumab-based regimens at the Ohio State University Comprehensive Cancer Center. We discover high rates of infections, hospital utilization, and severe lymphopenia and identify risks factors for severe lymphopenia, such as low pretreatment absolute lymphocyte count (ALC) values. Severe lymphopenia persists in 23% of patients, resulting in worst survival outcomes. Our data underline the importance of monitoring ALC and consider future use of prophylactic measures or alternative regimens in subsets of MM patients.
- Subjects :
- medicine.medical_specialty
Cancer Research
medicine.drug_class
Disease
CD38
Monoclonal antibody
outcomes
lcsh:RC254-282
03 medical and health sciences
0302 clinical medicine
immune system diseases
Internal medicine
hemic and lymphatic diseases
medicine
Clinical significance
infections
Adverse effect
Multiple myeloma
Original Research
business.industry
Daratumumab
Cancer
lymphopenia
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
daratumumab
myeloma
Oncology
030220 oncology & carcinogenesis
business
030215 immunology
Subjects
Details
- ISSN :
- 2234943X
- Volume :
- 10
- Database :
- OpenAIRE
- Journal :
- Frontiers in oncology
- Accession number :
- edsair.doi.dedup.....9c62355ba231ebbbd7c2ae316f1666d0